Aquestive Therapeutics, Inc. (AQST) 2024 Q2 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning and welcome to the Aquestive Therapeutics second quarter 2024 conference call. (Operator Instructions) As a reminder, this call will be recorded. I would now like to introduce your host for today's conference call Bennett Watson, of ICR Westwicke Investor Relations. You may begin.

    早安,歡迎參加 Aquestive Therapeutics 2024 年第二季電話會議。(接線員指示) 提醒您,本次通話將被錄音。現在我想介紹今天電話會議的主持人:ICR Westwicke 投資人關係的 Bennett Watson。您可以開始了。

  • Bennett Watson - IR

    Bennett Watson - IR

  • Thank you, operator. Good morning and welcome to today's call. On today's call, I'm joined by Dan Barber, Chief Executive Officer; and Ernie Toth, Chief Financial Officer. Who are going to provide an overview of recent business developments and performance for the second quarter 2024, followed by a Q&A session. During the Q&A session, the team will be joined by Dr. Carl Kraus, Chief Medical Officer; Dr. Stephen Wargacki, Chief Science Officer; and Sherry Korczynski, Senior Vice President of Sales and Marketing.

    謝謝,接線員。早安,歡迎參加今天的電話會議。今天與我一同出席的有執行長 Dan Barber,以及財務長 Ernie Toth。他們將概述近期業務發展與 2024 年第二季的表現,之後進行問答環節。在問答環節中,團隊也將加入首席醫療長 Carl Kraus 醫師、首席科學長 Stephen Wargacki 醫師,以及銷售與行銷資深副總裁 Sherry Korczynski。

  • As a reminder, the company's remarks today correspond with the earnings release that was issued after market close yesterday. In addition, a recording of today's call will be made available on a quest as website within the Investors section shortly following the conclusion of this call. To remind you, the Aquestive team will be discussing some non-GAAP financial measures this morning as part of its review of second quarter 2024 results. A description of these measures, along with the reconciliation to GAAP can be found in the earnings release issued yesterday, which is posted on the Investors section of Aquestive's website.

    提醒各位,公司今天的發言與昨日收盤後發布的財報新聞稿相對應。此外,今天的通話錄音將於本次通話結束後不久,於 Aquestive 網站「投資人」專區提供。再次提醒您,Aquestive 團隊今天上午在檢視 2024 年第二季業績時,將討論部分非 GAAP 財務衡量指標。這些衡量指標的說明以及與 GAAP 的調節表,可見於昨日發布並張貼於 Aquestive 網站「投資人」專區的財報新聞稿。

  • During the call, the company will be making forward-looking statements. We remind you of the company's safe harbor language as outlined in yesterday's earnings release as well as the risks and uncertainties affecting the company as described in the Risk Factors section and other sections included in the company's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024.

    在本次通話中,公司將作出前瞻性陳述。我們提醒您注意公司在昨日財報新聞稿中所載的「安全港」聲明,以及公司於 2024 年 8 月 6 日向美國證券交易委員會提交的 Form 10-Q 季度報告中「風險因素」章節及其他章節所描述、影響公司的風險與不確定性。

  • As with any pharmaceutical company with product candidates under development and products being commercialized, there are significant risks and uncertainties with respect to the company's business and the development, regulatory approval and commercialization of its products and other matters related to operations.

    如同任何擁有研發中候選產品並進行產品商業化的製藥公司,公司在業務、產品開發、監管核准與商業化,以及其他與營運相關事項方面,均存在重大風險與不確定性。

  • Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. Actual results may differ materially from these statements. All forward-looking statements attributable to a question or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement and the cautionary statements contained in the earnings release issued yesterday.

    鑑於這些不確定性,您不應過度依賴這些前瞻性陳述;其僅反映作出陳述當日的情況。實際結果可能與這些陳述存在重大差異。任何可歸因於提問者或任何代表其行事之人的所有前瞻性陳述,均在其整體範圍內明確受本項警示聲明以及昨日發布之財報新聞稿中警示聲明的限制。

  • The Company assumes no obligation to update its forward-looking statements after the date of this conference call, whether as a result of new information, future events or otherwise, except as required under applicable law.

    除非適用法律另有要求,公司在本次電話會議日期之後,無義務因新資訊、未來事件或其他原因更新其前瞻性陳述。

  • With that, I will now turn the line over to Dan.

    接下來,我把電話交給 Dan。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Thank you Bennett. On the heels of our successful equity raise in the first quarter, we had a very eventful second quarter. We progressed our Anaphylm epinephrine Sublingual Film program, gained FDA approval of Libervant diazepam Buccal Film to the 2 to 5 year old age group, streamlined our base business to focus on growth and continued to expand our Libervant launch efforts for epilepsy patients aged between 2 and 5 years. As usual with Aquestive, this was an action-packed 90 days.

    謝謝 Bennett。在第一季成功完成股權募資之後,我們第二季也非常忙碌、事件頻仍。我們推進了 Anaphylm 腎上腺素舌下薄膜計畫,取得 FDA 核准將 Libervant 地西泮頰黏膜薄膜適用年齡擴大至 2 至 5 歲族群,精簡基礎業務以聚焦成長,並持續擴大針對 2 至 5 歲癲癇患者的 Libervant 上市推廣工作。一如既往,對於 Aquestive 而言,這是行動滿檔的 90 天。

  • Starting with Anaphylm, our momentum continues to build. When I look at the competitive landscape for Anaphylm, I remain more optimistic than ever. With the potential to be the first and only oral epinephrine product for the treatment of severe allergic reactions, including anaphylaxis. We believe Anaphylm easily fits within the patient's daily life due to its highly differentiated product attributes.

    先從 Anaphylm 談起,我們的動能持續增強。當我觀察 Anaphylm 的競爭格局時,我比以往任何時候都更樂觀。Anaphylm 有望成為首個且唯一的口服腎上腺素產品,用於治療嚴重過敏反應(包括過敏性休克)。我們相信,憑藉其高度差異化的產品特性,Anaphylm 能輕鬆融入患者的日常生活。

  • On past earnings calls, I have focused on some of these important attributes such as ease of carrying and ease of use. Today, let me expand on an additional area of differentiation. Let's talk about the durability of rescue products in the real world. You see approved epinephrine medical devices such as auto-injectors come in liquid form and are largely made up of water. Products composed largely of water are subject to degradation in real-world conditions like high temperatures.

    在過去的財報電話會議中,我曾聚焦於一些重要特性,例如便於攜帶與便於使用。今天,我想延伸談談另一個差異化面向。我們來談談急救產品在真實世界中的耐受性與耐用性。您會看到已核准的腎上腺素醫療器材(例如自動注射器)為液體形式,且主要成分是水。以水為主要成分的產品,在高溫等真實世界條件下容易發生降解。

  • That is one of the main reasons that EpiPens have such strict storage instructions, as they may no longer be effective if they are left on a soccer field in summer heat for an extended period of time. We estimate that 98% of the EpiPen formulation is water. Now think about Anaphylm. Only 2% of the Anaphylm product is composed of water. As we have seen with our other products over the last two decades, oral films are different.

    這也是 EpiPen 具有嚴格儲存指示的主要原因之一;例如在夏季高溫下若長時間放在足球場上,可能就不再有效。我們估計 EpiPen 配方中有 98% 是水。現在想想 Anaphylm。Anaphylm 產品中只有 2% 由水構成。正如我們在過去二十年其他產品上所見,口溶薄膜是不同的。

  • Anaphylm's low water content means it has the potential to remain stable even after long durations of heat exposure. It means Anaphylm has the potential to still work in freezing temperatures. It means Anaphylm has the potential to work in a broad spectrum of real-world conditions, which we do not believe can be matched by any other existing or pipeline product in this category.

    Anaphylm 的低含水量意味著,即使長時間暴露於高溫下,也有望保持穩定。這意味著 Anaphylm 在冰凍溫度下也有望仍然有效。這意味著 Anaphylm 有望在廣泛的真實世界條件下發揮作用,而我們認為在此類別中,任何其他既有產品或研發中產品都無法匹敵。

  • Now turning to our development progress. We have successfully completed two of the three supportive studies necessary for engaging the FDA in a pre-NDA meeting. These are our temperature/pH study and self-administration study. In both cases, as we have already shared publicly, the top line data was positive. The third study, our oral allergen challenge study, is currently in the clinic. We are advancing our enrollment of the patients needed for the study and expect completion of the study late in the third quarter or early in the fourth quarter of this year.

    接著談研發進展。我們已成功完成與 FDA 進行 NDA 前會議所需的三項支持性研究中的兩項。這兩項分別是溫度/pH 研究與自我給藥研究。在這兩項研究中,正如我們先前已公開分享的,主要數據結果為正向。第三項研究,也就是我們的口服過敏原激發試驗,目前正在臨床進行中。我們正在推進該研究所需患者的入組,並預期於今年第三季末或第四季初完成研究。

  • We continue to anticipate holding a pre-NDA meeting in the fourth quarter and starting our pediatric study immediately afterwards. Once the pediatric study has completed, we will file our NDA. At this time, we expect to begin our NDA submission in December and complete the submission in the first quarter of 2025. Based on FDA approval, our timing for a full launch at the end of 2025 or in the first quarter of 2026 remains unchanged.

    我們仍預期在第四季召開 NDA 前會議,並在其後立即啟動兒科研究。兒科研究完成後,我們將提交 NDA。目前我們預期於 12 月開始 NDA 送件,並在 2025 年第一季完成送件。基於 FDA 核准進度,我們對於在 2025 年底或 2026 年第一季全面上市的時程預期維持不變。

  • Our commercial launch activities remain on track. We now have in place very experienced leadership over both our commercial and medical affairs efforts for Anaphylm. The team is focused on increasing awareness among physicians, payers, and the advocacy community. Across this entire stakeholder universe, we are hearing that Anaphylm is the answer to address the significant unmet needs of healthcare providers, patients, and their caregivers.

    我們的商業化上市準備工作仍按計畫推進。目前我們已為 Anaphylm 的商業與醫藥事務工作配置了經驗非常豐富的領導團隊。團隊聚焦於提升醫師、支付方以及倡議社群的認知。在整個利害關係人範疇中,我們聽到的回饋是:Anaphylm 正是用以解決醫療照護提供者、患者及其照護者重大未被滿足需求的答案。

  • Even though other alternative medical devices may be on the horizon, there is nothing like Anaphylm, no needle, no device, oral administration. Anaphylm is easy to carry and keep everywhere you go, whether you are headed to the beach or the soccer field. There's no need for a carrying case, Anaphylm fits on the back of your phone or easily in a wallet and is durable enough to withstand the real-life activities of patients, all while potentially improving the carry rate for patients.

    即使未來可能會出現其他替代性醫療器材,但沒有任何產品能像 Anaphylm 一樣:無針、無裝置、口服給藥。Anaphylm 易於攜帶並可隨身放置於任何地方,不論您是要去海邊或足球場。不需要攜帶盒,Anaphylm 可貼在手機背面或輕鬆放入錢包,且足夠耐用以承受患者的日常活動,同時有望提升患者的隨身攜帶率。

  • Our data suggests Anaphylm is not impacted by comorbid allergic diseases such as congestion, atopic dermatitis, and asthma. Anaphylm remains highly differentiated and poised to positively disrupt rescue treatment for severe allergic reactions, including anaphylaxis.

    我們的數據顯示,Anaphylm 不受鼻塞、異位性皮膚炎與氣喘等共病過敏性疾病的影響。Anaphylm 仍具高度差異化,並有望對嚴重過敏反應(包括過敏性休克)的急救治療帶來正向的顛覆性影響。

  • As we get closer to filing and launch, we have had multiple inbound inquiries from companies interested in helping us distribute Anaphylm. Our goal is to maximize the distribution of Anaphylm to all patients immediately if approved by the FDA. Over the next year, we will continue to examine if our commercial efforts can be augmented by utilizing the sales and distribution platforms of other companies.

    隨著我們逐步接近申報與上市,我們已收到多家有意協助我們分銷 Anaphylm 的公司主動洽詢。我們的目標是在獲 FDA 核准後,立即將 Anaphylm 的可及性最大化,讓所有患者都能取得。在未來一年,我們將持續評估是否可透過其他公司的銷售與分銷平台來強化我們的商業化工作。

  • Speaking of commercialization, let's turn to Libervant. We are now focused on expanding our Libervant launch in the 2 to 5 year old age group. Over the last few months, we have received significant feedback on the value and benefits Libervant offers to patients and their caregivers. This feedback includes outreach for major children's institutions across the country who are proactively seeking information on Libervant.

    談到商業化,接下來我們把焦點轉向 Libervant。我們目前專注於擴大 Libervant 在 2 至 5 歲年齡層的上市推廣。過去幾個月,我們收到大量關於 Libervant 為患者及其照護者帶來價值與效益的回饋。這些回饋包括來自全國主要兒童醫療機構的接洽,他們正主動尋求 Libervant 的相關資訊。

  • We expect to have national retail distribution capabilities in place by October 1, while continuously improving our commercial and Medicaid coverage through the fourth quarter. We will expand to a national sales team of 10 representatives in late Q3. We believe expanding our sales team for Libervant for the 2 to 5 year old age group will result in minimal single-digit millions in cash burn in 2025 and will generate top-line revenue in 2025 to be somewhere in the neighborhood of $5 million.

    我們預期在 10 月 1 日前建立全國零售通路的分銷能力,並在第四季持續改善我們的商業化執行與 Medicaid 給付覆蓋。我們將在第三季末把全國銷售團隊擴編至 10 名業務代表。我們相信,為 2 至 5 歲年齡層擴大 Libervant 的銷售團隊,將在 2025 年帶來數百萬美元等級、個位數百萬的現金消耗,並在 2025 年創造營收,預估約在 500 萬美元左右。

  • While that may seem modest in the short term, there is significant benefit to the company as we prepare for our Anaphylm launch in 2026 if approved, and a full Libervant launch in 2027 on the expiration of a competitor's orphan drug exclusivity. We continue to see the long-term potential for Libervant as a brand with over $100 million in peak annual net sales, and we look forward to our sales expansion in the 2 to 5 year old age group in the weeks to come.

    雖然短期看起來可能不算顯著,但在我們為 Anaphylm(若獲核准)於 2026 年上市,以及在競品孤兒藥獨占期於 2027 年到期後進行 Libervant 全面上市做準備之際,這將為公司帶來顯著效益。我們仍看好 Libervant 作為品牌的長期潛力,峰值年度淨銷售額可超過 1 億美元;並期待在未來幾週推進 2 至 5 歲年齡層的銷售擴張。

  • Now let's turn to our Adrenaverse epinephrine prodrug platform. As promised, we are preparing to share more with the investor community on the future pipeline potential of Adrenaverse. As you may recall, Anaphylm was born out of our Adrenaverse platform technology. We believe there are additional major products that will come from this platform.

    接下來我們談談 Adrenaverse 腎上腺素前藥平台。如先前承諾,我們正準備向投資人社群分享更多關於 Adrenaverse 未來產品線潛力的資訊。各位或許記得,Anaphylm 正是源自我們的 Adrenaverse 平台技術。我們相信,這個平台還將孕育出其他重要產品。

  • In the next few months, we will hold an Investor Day to outline how Anaphylm has helped propel our scientific thinking, the science behind our Adrenaverse platform, our unique intellectual property position, and the potential products that could arise from the work we have done. This is an exciting part of our business.

    在接下來幾個月,我們將舉辦投資人日,說明 Anaphylm 如何推動我們的科學思維、Adrenaverse 平台背後的科學、我們獨特的智慧財產權布局,以及我們已完成的工作可能衍生出的潛在產品。這是我們業務中令人振奮的一部分。

  • Finally, on our base business, we have completed our strategic review of our existing collaborations and eliminated our unprofitable relationships. This includes no longer focusing on China as well as terminating our US based partnership for the distribution of Exservan riluzole Oral Film. In 2023, Aquestive's revenue from Exservan was negligible. Ernie will provide more details on revenue in a moment.

    最後,關於我們的基礎業務,我們已完成對既有合作的策略性檢視,並淘汰不具獲利性的合作關係。其中包括不再將中國作為重點,以及終止我們在美國的合作夥伴關係(用於分銷 Exservan riluzole 口服薄膜)。在 2023 年,Aquestive 來自 Exservan 的營收微乎其微。Ernie 稍後將提供更多關於營收的細節。

  • Eliminating these distractions will allow the executives responsible for our base business to focus on products such as Suboxone, Emily with Zambon, , Sympazan with Assertio and KYNMOBI with Sunovion and Hypera while also preparing for higher volumes of Libervant and the launch of Anaphylm, if approved.

    排除這些分心事項後,負責基礎業務的管理團隊將能專注於 Suboxone、與 Zambon 合作的 Emily、與 Assertio 合作的 Sympazan,以及與 Sunovion 與 Hypera 合作的 KYNMOBI 等產品,同時也為 Libervant 更高的出貨量以及 Anaphylm(若獲核准)的上市做準備。

  • In conclusion, we continue to be a company with incredible growth potential. Our lead pipeline program, Anaphylm for severe allergic reactions, including anaphylaxis is nearing the end of its development cycle, and we believe it is only months away from filing. Our commercial product Libervant, affords us the opportunity to begin commercialization in a low-risk, low-cost environment while still retaining significant long-term potential. Our Adrenaverse platform gives us a unique intellectual property position that can generate meaningful programs for years to come, and our base business continues to be a meaningful part of our story.

    總結而言,我們仍是一家具備驚人成長潛力的公司。我們的主要研發管線項目 Anaphylm(用於嚴重過敏反應,包括過敏性休克)正接近開發週期尾聲,我們相信距離申報僅剩數月。我們的商業化產品 Libervant,讓我們得以在低風險、低成本的環境中啟動商業化,同時仍保有顯著的長期潛力。Adrenaverse 平台賦予我們獨特的智慧財產權地位,可在未來多年持續產出具意義的研發項目,而我們的基礎業務也仍是我們故事中重要的一環。

  • With that, I will turn the call over to Ernie.

    接下來,我把電話會議交給 Ernie。

  • Ernie Toth - Chief Financial Officer, Senior Vice President

    Ernie Toth - Chief Financial Officer, Senior Vice President

  • Thank you, Dan, and good morning, everyone. By now you will have seen our financial results in our earnings release that was issued last evening. As we typically do, we will address most of the discussion related to the second quarter 2024 results in the Q&A. During the second quarter, we continued to execute on our financial strategy to strengthen our financial position to support the continued development of Anaphylm. Our lead product candidate that has no needle is not a device is orally administered and is easy to carry.

    謝謝你,Dan,各位早安。到目前為止,各位應該已在昨晚發布的財報新聞稿中看到我們的財務結果。如同以往,我們將在問答環節處理大部分與 2024 年第二季結果相關的討論。在第二季,我們持續執行財務策略,以強化財務狀況,支持 Anaphylm 的持續開發。我們的主要候選產品不需要針頭、不是裝置、採口服給藥且便於攜帶。

  • On April 26, we received approval for Libervant for ages between two and five. Second quarter revenue for Libervant was minimal due to limited launch activities. But we expect to expand our launch for this pediatric age group during the remainder of the year with broadening national retail distribution and expanded insurance coverage. We continued our pre-commercial launch activities for Anaphylm to increase awareness among physicians, payers and the advocacy community.

    4 月 26 日,我們取得 Libervant 針對 2 至 5 歲族群的核准。由於上市活動有限,Libervant 第二季營收很少。但我們預期在今年剩餘期間,透過擴大全國零售通路分銷與擴增保險覆蓋,來擴大此兒科年齡層的上市推廣。我們也持續進行 Anaphylm 的上市前商業化活動,以提升醫師、支付方與倡議社群的認知。

  • In addition, during the quarter we conducted a strategic review of our existing collaborations with a prioritization of our focus on promising products from a long term profitability perspective, we terminated our US and China based collaborations for Exservan, allowing us to focus on the continued development of Anaphylm, our pipeline and commercialization of Libervant for patients aged between two and five.

    此外,本季我們對既有合作進行策略性檢視,並以長期獲利能力角度優先聚焦具前景的產品;我們終止了 Exservan 在美國與中國的合作,使我們能專注於 Anaphylm 的持續開發、我們的研發管線,以及 Libervant 在 2 至 5 歲患者族群的商業化。

  • Now let's turn to the second quarter results. Total revenues increased from $13.2 million in the second quarter of 2023 to $20.1 million in the second quarter of 2024. This 52% increase in revenue was primarily driven by increases in license and royalty revenue due to the recognition of deferred revenues from the termination of licensing and supply agreements, partially offset by decreases in manufacture and supply revenue. Excluding this one-time recognition of deferred revenue, total revenues decreased by $3.4 million or 26% year over year.

    現在我們來看第二季的業績。總營收由 2023 年第二季的 1,320 萬美元增加至 2024 年第二季的 2,010 萬美元。營收增加 52% 主要來自授權與權利金收入的增加,原因是終止授權與供應協議而認列遞延收入;但部分被製造與供應收入下降所抵銷。若排除這次一次性遞延收入認列,總營收年減 340 萬美元,或 26%。

  • Manufacture and supply revenue decreased from $11.6 million in the second quarter 2023 to $8.1 million in the second quarter 2024, primarily due to timing of Suboxone and on deep orders. Co-development and research fees increased by $0.6 million for the second quarter 2024 versus the prior year period. Total revenues increased from $24.4 million for the six months ended June 30, 2023, to $32.2 million for the six months ended June 30, 2024. This 32% increase in revenue was primarily driven by the increases in license and royalty revenue due to the recognition of deferred revenues from the termination of licensing and supply agreements, partially offset by decreases in manufacture and supply revenue.

    製造與供應收入由 2023 年第二季的 1,160 萬美元降至 2024 年第二季的 810 萬美元,主要因 Suboxone 與 on deep 訂單的時點影響。共同開發與研究費用在 2024 年第二季較去年同期增加 60 萬美元。截至 2023 年 6 月 30 日止六個月的總營收為 2,440 萬美元,而截至 2024 年 6 月 30 日止六個月的總營收為 3,220 萬美元。營收增加 32% 主要來自授權與權利金收入的增加,原因是終止授權與供應協議而認列遞延收入;但部分被製造與供應收入下降所抵銷。

  • Excluding this one-time recognition of deferred revenue, total revenues decreased by $2.5 million or 10.3% year over year. Excluding the onetime retroactive 2022 price increase of $1.7 million recognized in the six months ended June 30, 2023, manufacture and supply revenue decreased by 5%, primarily due to lower [this] revenue, which was attributable to a decrease in volume due to timing of orders, partially offset by an increase in Suboxone manufacturing revenue.

    排除這筆一次性遞延收入認列後,總營收年減250萬美元,或10.3%。排除截至2023年6月30日止六個月內認列的170萬美元一次性追溯性2022年調價影響後,製造與供應收入下降5%,主要由於此項收入較低,係因訂單時點造成出貨量下降所致,部分被Suboxone製造收入增加所抵銷。

  • Research and development expenses increased from $3.5 million in the second quarter 2023 to $4.2 million in the second quarter of 2024. The increase in research and development expenses was primarily due to clinical trial costs associated with the continued advancement of our Anaphylm program, an increase in personnel costs and an increase in share-based compensation. As a reminder, the first three quarters of 2024 will contain expenses for multiple clinical studies being conducted to advance the Anaphylm program.

    研發費用由2023年第二季的350萬美元增加至2024年第二季的420萬美元。研發費用增加主要係因與我們持續推進Anaphylm計畫相關的臨床試驗成本、員工人事成本增加,以及股份基礎給付增加。提醒一下,2024年前三季將包含為推進Anaphylm計畫而進行的多項臨床研究費用。

  • Research and development expenses increased from $7 million for the six months ended June 30, 2023, to $10.1 million for the six months ended June 30, 2024. The increase in research and development expenses was primarily due to the clinical trial costs associated with the continued advancement of the Anaphylm program and increase in personnel costs and the increase in share-based compensation.

    研發費用由截至2023年6月30日止六個月的700萬美元增加至截至2024年6月30日止六個月的1,010萬美元。研發費用增加主要係因與持續推進Anaphylm計畫相關的臨床試驗成本、員工人事成本增加,以及股份基礎給付增加。

  • Selling, general and administrative expenses increased from $7.4 million in the second quarter of 2023 to $11.4 million in the second quarter 2024. The increase of $4 million or 54% primarily represents higher personnel costs of approximately $0.5 million, share-based compensation expense of $0.6 million, regulatory and licensing fees of $0.4 million related to the regulatory fee for Libervant, consulting cost of $0.7 million, higher expenses of $1.5 million due to a change in the allocation of manufacture and supply costs compared to the prior period and other expenses partially offset by decreases in other general and administrative costs, including insurance expense.

    銷售、一般及行政費用由2023年第二季的740萬美元增加至2024年第二季的1,140萬美元。增加的400萬美元(或54%)主要包括:員工人事成本約增加50萬美元、股份基礎給付費用60萬美元、與Libervant監管費用相關的法規與許可費40萬美元、顧問費70萬美元、因製造與供應成本分攤方式相較前期變動而增加的150萬美元費用,以及其他費用;部分被其他一般及行政成本(包括保險費用)下降所抵銷。

  • Selling, general and administrative expenses increased from $14.8 million for the six months ended June 30, 2023 to $22 million for the six months ended June 30, 2024. Of the increase of 49% or $7.2 million for the six months ended June 30, 2024, as compared to the same period in the prior year. More than half of this increase was driven by severance costs of $1.1 million incurred in the first three months of this year, and $2.5 million due to a year-over-year change in the allocation of manufacture and supply costs.

    銷售、一般及行政費用由截至2023年6月30日止六個月的1,480萬美元增加至截至2024年6月30日止六個月的2,200萬美元。截至2024年6月30日止六個月相較前一年同期,增加49%或720萬美元。此增幅超過一半係由今年前三個月發生的110萬美元資遣費用,以及因製造與供應成本分攤方式年對年變動而增加的250萬美元所帶動。

  • The remainder of the increase is largely driven by higher commercial and regulatory costs related to Libervant and Anaphylm, partially offset by lower legal fees and decreases in other general and administrative costs, including insurance.

    其餘增幅主要來自與Libervant與Anaphylm相關的商業化與法規成本較高,部分被較低的法律費用及其他一般及行政成本(包括保險)下降所抵銷。

  • Aquestive's net loss for the second quarter of 2024 was $2.7 million or $0.03 for both basic and diluted loss per share. Compared to the net loss for the second quarter of 2023 of $5.8 million for $0.10 for both basic and diluted loss per share. The decrease in net loss was driven by increases in revenue and decreases in manufacture and supply expenses, offset by increases in selling, general and administrative expenses research and development expenses and non-cash interest expense related to the amortization of the debt and royalty obligation discount.

    Aquestive於2024年第二季的淨損為270萬美元,基本及稀釋每股虧損均為0.03美元。相較之下,2023年第二季淨損為580萬美元,基本及稀釋每股虧損均為0.10美元。淨損減少主要由營收增加及製造與供應費用下降所帶動,但部分被銷售、一般及行政費用增加、研發費用增加,以及與債務及權利金義務折價攤銷相關的非現金利息費用增加所抵銷。

  • Aquestive's net loss for the six months ended June 30, 2024 was $15.6 million or $0.19 for both basic and diluted loss per share compared to the net income for the six months ended June 30, 2023 of $2.3 million or $0.04 for both basic and diluted earnings per share. The increase in net loss was primarily driven by a decrease in net other income, increases in selling, general and administrative expenses, research and development expenses and non-cash interest expense related to the amortization of the debt and royalty obligation discounts, partially offset by increases in revenues and decreases in manufacture and supply expense.

    截至2024年6月30日止六個月,Aquestive淨損為1,560萬美元,基本及稀釋每股虧損均為0.19美元;相較之下,截至2023年6月30日止六個月淨利為230萬美元,基本及稀釋每股盈餘均為0.04美元。淨損增加主要係因其他淨收益下降、銷售、一般及行政費用增加、研發費用增加,以及與債務及權利金義務折價攤銷相關的非現金利息費用增加;部分被營收增加及製造與供應費用下降所抵銷。

  • Non-gaap adjusted EBITDA income was $1.8 million in the second quarter of 2024 compared to non-GAAP adjusted EBITDA loss of $3.3 million in the second quarter of 2023. Non-GAAP adjusted EBITDA income, excluding adjusted R&D expenses, was $5.6 million in the second quarter of 2024 compared to a non-GAAP adjusted EBITDA income, excluding adjusted R&D expenses of $0.1 million in the second quarter 2023.

    2024年第二季非GAAP調整後EBITDA為180萬美元盈餘,相較2023年第二季非GAAP調整後EBITDA為330萬美元虧損。排除調整後研發費用之非GAAP調整後EBITDA,2024年第二季為560萬美元盈餘,相較2023年第二季排除調整後研發費用之非GAAP調整後EBITDA為10萬美元盈餘。

  • Non-gaap adjusted EBITDA loss was $5.4 million for the six months ended June 30, 2024, compared to non-GAAP adjusted EBITDA loss of $7.2 million for the six months ended June 30, 2023. Non-GAAP adjusted EBITDA income, excluding adjusted R&D expenses, was $4.2 million for the six months ended June 30, 2024, compared to a non-GAAP adjusted EBITDA loss excluded adjusted R&D expenses of $0.4 million for the six months ended June 30, 2023.

    截至2024年6月30日止六個月,非GAAP調整後EBITDA為540萬美元虧損,相較截至2023年6月30日止六個月非GAAP調整後EBITDA為720萬美元虧損。排除調整後研發費用之非GAAP調整後EBITDA,截至2024年6月30日止六個月為420萬美元盈餘,相較截至2023年6月30日止六個月排除調整後研發費用之非GAAP調整後EBITDA為40萬美元虧損。

  • Cash and cash equivalents were approximately $90 million as of June 30, 2024. During the second quarter, we did not sell any shares under our ATM facility. We continue to be focused in 2024 on the advancement of our Anaphylm epinephrine program and continued commercialization of Libervant for patients ages between two and five years old.

    截至2024年6月30日,現金及約當現金約為9,000萬美元。於第二季期間,我們未透過ATM融資機制出售任何股份。2024年我們仍聚焦於推進Anaphylm腎上腺素計畫,以及持續推動Libervant在2至5歲患者族群的商業化。

  • As outlined in the press release issued last night after market close, we are revising our outlook for 2024 as follows. Total revenues of approximately $57 million to $60 million from prior revenue guidance of $48 million to $51 million. And non-GAAP adjusted EBITDA loss of approximately $20 million to $23 million from prior guidance of $22 million to $26 million.

    如昨晚收盤後發布的新聞稿所述,我們將2024年展望修正如下。總營收約為5,700萬至6,000萬美元,高於先前營收指引的4,800萬至5,100萬美元。非GAAP調整後EBITDA虧損約為2,000萬至2,300萬美元,優於先前指引的2,200萬至2,600萬美元。

  • Our guidance for 2024 includes conclusion of the supportive studies engaging the FDA in a pre-NDA meeting commencing a pediatric study found the NDA and precommercial activities for Anaphylm in addition to expanding the commercial launch of Libervant for patients ages between two and five.

    我們對2024年的指引包括:完成支持性研究、在NDA送件前與FDA進行pre-NDA會議、啟動一項兒科研究、推進Anaphylm的NDA與上市前商業活動,並擴大Libervant在2至5歲患者族群的商業上市推廣。

  • With that, I will now turn the line back to the operator to open the line for questions.

    接下來,我將把電話交回給接線員,開放提問。

  • Operator

    Operator

  • Thank you. (Operator Instructions)

    謝謝。(接線員指示)

  • Roanna Ruiz, Leerink Partners.

    Roanna Ruiz,Leerink Partners。

  • Roanna Ruiz - Analyst

    Roanna Ruiz - Analyst

  • Great. Good morning, everyone. So two questions for me. First one, I was curious about the upcoming launch preparations for Anaphylm. Could you talk a bit about your overall plan to target key physicians and hospital accounts and how might you pursue possibly unbranded marketing and engaging with advocacy groups alongside that?

    很好。各位早安。我有兩個問題。第一個,我想了解Anaphylm即將上市的準備工作。能否談談你們鎖定關鍵醫師與醫院客戶的整體規劃?以及你們可能會如何推動未掛品牌的行銷,並同時與倡議團體互動?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Good morning, Roanna, nice to hear your voice. So I've been very fortunate today on this call that as we've invested in our company, I have a phenomenal leader of Commercial with me named, Sherry Korczynski who actually has a deep background in the epinephrine space. So I'm going to hand it over to Sherry to walk you through the awareness activity we're doing right now and some of her thoughts on our Anaphylm launch.

    早安,Roanna,很高興聽到你的聲音。今天在這通電話會議上,我很幸運的是,隨著我們對公司進行投資,我身邊有一位非常出色的商業化領導者Sherry Korczynski,她在腎上腺素領域其實有深厚背景。所以我會把時間交給Sherry,請她帶你了解我們目前正在進行的認知提升活動,以及她對我們Anaphylm上市的部分想法。

  • Sherry Korczynski - Senior Vice President of Sales and Marketing

    Sherry Korczynski - Senior Vice President of Sales and Marketing

  • Good morning, everybody. I'm super excited to be here, and I cannot be more thrilled at the opportunities we have with meeting significant unmet need in the severe allergy market. As we think about what we're doing today to prepare for our launch in late '25, early '26, really focused on implementing a three pronged strategy that targets high auto-injector prescribers. And this encompasses first, obviously, awareness of the data and the functional benefits of Anaphylm. Secondly, believability in Anaphylm that it works as at least as well as the EpiPen based on the data we have. And third, we want to ensure there is confidence to prescribe Anaphylm when approved.

    各位早安。我非常興奮能在這裡,也對我們在重度過敏市場中滿足重大未被滿足需求所帶來的機會感到無比振奮。當我們思考為了在 2025 年底、2026 年初的上市所做的準備時,我們確實聚焦於落實一個三管齊下的策略,鎖定高頻開立自動注射器的處方醫師。這首先當然包括提升對 Anaphylm 數據與功能性優勢的認知。第二,是基於我們現有數據,建立對 Anaphylm 的信心,相信它的效果至少與 EpiPen 一樣好。第三,我們希望在獲批後,確保醫師對開立 Anaphylm 具有充分信心。

  • So to achieve this and to answer your question a little bit more detailed, we've put significant effort into every key areas, as you would expect at this time in preparation for launch. The first is around medical education and KOL interactions. So we're out of the allergy conferences, we are consistently meeting with the top four advocacy groups. We have engaged to start CME and non-CME programs, leverage through channels the doctors access for information.

    因此,為了達成這些目標,也更詳細地回答你的問題,我們在上市準備階段如你所預期,已在每個關鍵領域投入大量心力。第一個面向是醫學教育與 KOL 互動。我們出席各類過敏相關會議,並持續與四大倡議團體會面。我們也已著手推動 CME 與非 CME 專案,並透過醫師取得資訊的管道加以運用。

  • Secondly, we're doing all of our block and tackling marketing activities to prepare Anaphylm for launch day. This is market research with the high prescribers, our brand building work such as positioning, advertising concepts, key messaging and perhaps most importantly, we're having conversations, have started with key payer decision-makers so that at or shortly after PDUFA, we ensure that patients have affordable access to Anaphylm.

    第二,我們正在進行所有基礎且必要的行銷作業,為 Anaphylm 的上市日做準備。這包括針對高處方量醫師的市場調研、品牌建立工作(例如定位、廣告概念、關鍵訊息),以及或許最重要的是,我們已開始與關鍵的付款方決策者對話,確保在 PDUFA 當下或不久之後,病患能以可負擔的方式取得 Anaphylm。

  • Roanna Ruiz - Analyst

    Roanna Ruiz - Analyst

  • Got it. That's super helpful. And then second one for me. Could you remind us from the recent temperature/pH and self-administration studies, how the PD data tracked with the PK data when you looked at the data in these studies? And do you plan to disclose the exact specifics coming up in the fall?

    了解。這非常有幫助。那我第二個問題。你能否提醒我們,在近期的溫度/pH 與自我給藥研究中,當你們檢視這些研究數據時,PD 數據與 PK 數據的走勢對應情況如何?以及你們是否計畫在今年秋天披露更精確的細節?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Sure. So Roanna, I'm going to hand it over to Dr. Kraus in a second here, just a technical note, I'll call it, in our supplementary materials online, we actually did include the PD data for our temperature/pH study, but I'll let Dr. Kraus give you his view on the results.

    當然。Roanna,我等一下把問題交給 Kraus 醫師;先補充一個技術性說明:在我們線上補充資料中,其實已納入溫度/pH 研究的 PD 數據,但我會讓 Kraus 醫師分享他對結果的看法。

  • Carl Kraus - Chief Medical Officer

    Carl Kraus - Chief Medical Officer

  • Yes, happy to, and thanks for the question. The pharmacodynamic data, as we've seen in the past, does reflect the pharmacokinetic data in our data set historically, and we see the same kind of tracking both in the temperature/pH study as well as in the self-administration study. So I think, overall there is consistency across our data set.

    好的,很樂意,也謝謝你的提問。藥效學(PD)數據如同我們過去所見,在我們歷史數據集中確實反映了藥物動力學(PK)數據;而在溫度/pH 研究以及自我給藥研究中,我們也看到同樣的對應追蹤關係。因此我認為,整體而言,我們的數據集呈現一致性。

  • Roanna Ruiz - Analyst

    Roanna Ruiz - Analyst

  • Got it. Thanks for clarifying.

    了解。謝謝澄清。

  • Operator

    Operator

  • David Amsellem, Piper Sandler.

    David Amsellem,Piper Sandler。

  • David Amsellem - Analyst

    David Amsellem - Analyst

  • Hey, thanks. Just a couple for me. So first, can you talk more specifically about the design of the pediatric study? And I believe, so that's something you're going to be discussing with the FDA in your pre-NDA meeting, if I'm not mistaken. So can you elaborate on the discussion points? And what if anything needs to be, I guess, ironed out with the agency as it relates to the pediatric. I'm sorry, that's number one.

    嗨,謝謝。我有幾個問題。首先,你能更具體談談兒科研究的設計嗎?而且我相信,如果我沒記錯的話,這是你們會在 pre-NDA 會議中與 FDA 討論的事項。所以你能否說明一下討論重點?以及就兒科相關而言,還有哪些需要與主管機關進一步釐清或敲定的地方?抱歉,這是第一個問題。

  • Number two, on Libervant, can you talk more about your long-term strategy for the asset? Is the idea here to ultimately out-license it or are you contemplating keeping it? I just want to get your latest and greatest on how you're thinking about the role of that asset in the business. Thanks.

    第二個問題,關於 Libervant,你能多談談你們對這項資產的長期策略嗎?你們的想法是最終將其對外授權(out-license),還是考慮自行保留?我想了解你們最新對這項資產在公司業務中角色的思考。謝謝。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Sure. Good morning, David. So on the pediatric study, I know Dr. Kraus and his team have spent a lot of time on this, so I'll let you get his view on your question.

    好的。早安,David。關於兒科研究,我知道 Kraus 醫師和他的團隊在這上面投入了很多時間,所以我先請他來回答你的問題。

  • Carl Kraus - Chief Medical Officer

    Carl Kraus - Chief Medical Officer

  • Yeah, thanks for the question. On the pediatric study, fortunately, the trial design is relatively straightforward. The intention of the study would be to determine whether the pharmacokinetic profile is able to mirror what we're seeing in adults. So I don't expect that to be a complicated design and one which we, of course, will need to secure alignment with the agency.

    好的,謝謝你的提問。就兒科研究而言,所幸試驗設計相對直接。這項研究的目的,是判定其藥物動力學(PK)曲線是否能夠對應我們在成人身上看到的結果。因此我不預期會是複雜的設計;當然,我們也需要與主管機關取得一致。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • And David, just to add to Dr. Kraus' view, just two reminders. Once again, in our supplementary materials, we have the design for people to see. And two, we have shared that with the FDA before. So this is an ongoing discussion that Carl and his team are having.

    David,我再補充 Kraus 醫師的看法兩點提醒。第一,再次強調,我們在補充資料中已提供該設計供大家查看。第二,我們之前也已與 FDA 分享過。因此,這是 Carl 與其團隊正在持續進行的討論。

  • On your second question on Libervant, I'm really glad you asked that question because with all of the focus we have on Anaphylm in our company and outside of our company, sometimes Libervant gets overshadowed. But Libervant is a -- in my view, a fantastic product for patients. The differentiation we offer in this space, the fact that it's the only oral product available to the 2 to 5 year old patient group is, in my mind, truly disruptive in that space. And we think as we get to 2027 and are able to launch across all the age groups that will continue to unfold.

    至於你第二個關於 Libervant 的問題,我很高興你問到,因為無論在公司內外,大家的焦點多放在 Anaphylm 上,Libervant 有時會被掩蓋。但在我看來,Libervant 對病患而言是一個非常出色的產品。我們在這個領域提供的差異化——它是唯一可用於 2 到 5 歲病患族群的口服產品——在我看來確實對該領域具有顛覆性。而我們認為,當我們走到 2027 年並能夠在所有年齡層上市時,這一點將會持續展現出來。

  • So our mandate as a company is to make sure one patients have the product, and two, that we maximize our upside and our position in the product. As of today, that means we are putting together and launching a small -- or excuse me, expanding a small sales team. Like any of our products over time, it could remain with us for 10 years or it could end up being distributed by another company in the years to come. I think that remains to be seen.

    因此,公司目前的任務是:第一,確保病患能取得產品;第二,最大化我們在該產品上的上行空間與市場地位。截至目前,這代表我們正在組建並推出一個小型——抱歉,是擴編一個小型銷售團隊。如同我們其他產品一樣,隨著時間推移,它可能會由我們持有 10 年,也可能在未來幾年由另一家公司來經銷。我認為這仍有待觀察。

  • David Amsellem - Analyst

    David Amsellem - Analyst

  • Okay. That's helpful. If I may just sneak in a follow-up question on Libervant. So as you get to '27 and with the ODE situation in the rearview mirror. I guess the question is, if you were to keep it, what kind of commercial infrastructure would you put behind it more broadly than what you're doing now, how many reps, et cetera, et cetera?

    好的。這很有幫助。如果可以的話,我想再追問一個關於 Libervant 的問題。當你們走到 2027 年、且 ODE 的情況已成過去式時,我的問題是:如果你們選擇保留它,你們會在更廣泛層面上配置什麼樣的商業化基礎建設,會有多少業務代表等等?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yeah. Well, Libervant is a much narrower call point compared to Anaphylm. So you're talking about epileptologists who are, by far the majority prescribers in that space, and our plans that we originally had when we thought we were launching Libervant years ago remain evergreen. So the rep size would be limited, and we do not see that as a major lift as we get to 2027. I'm just looking at Sherry. Sherry, is there anything you would want to add to that?

    是的。相較於 Anaphylm,Libervant 的拜訪對象範圍要窄得多。你談的是癲癇專科醫師(epileptologists),他們在該領域是絕大多數的處方來源;而我們原先在多年前以為會上市 Libervant 時所制定的計畫,至今仍然適用。因此,業務代表的規模會受到限制;我們不認為在走到 2027 年時這會是很大的負擔。我看一下 Sherry。Sherry,你有沒有什麼想補充的?

  • Sherry Korczynski - Senior Vice President of Sales and Marketing

    Sherry Korczynski - Senior Vice President of Sales and Marketing

  • Well, this is really exciting as Dan mentioned. I mean this is a game changer for patients and caregivers. We are really excited as we have been over the last couple of months. The outreach directly to us has been significant from patients, children's hospitals, various institutions with a strong desire to have Libervant in their armamentarium, if you will. So we are, as Dan mentioned, expanding our launch to have in a very targeted way as we continue to ensure that the patients ages two to five have access to Libervant.

    嗯,正如 Dan 提到的,這真的令人振奮。我的意思是,這對病患與照護者而言是顛覆性的改變。過去幾個月我們一直都非常興奮。病患、兒童醫院以及各類機構直接與我們聯繫的情況相當顯著,大家都強烈希望能把 Libervant 納入他們的治療工具箱(如果你願意這麼說的話)。因此,如 Dan 所提到的,我們正在擴大上市推進,但會以非常精準的方式進行,同時持續確保 2 至 5 歲的病患能夠取得 Libervant。

  • David Amsellem - Analyst

    David Amsellem - Analyst

  • Okay. That's helpful. Thank you.

    好的。這很有幫助。謝謝。

  • Operator

    Operator

  • François Brisebois, Oppenheimer.

    François Brisebois,Oppenheimer。

  • François Brisebois - Analyst

    François Brisebois - Analyst

  • Hi, Thanks for taking the questions. Congrats on the progress. I was just wondering, in terms of the oral allergy test and that data coming now, you talked about completion. But is completion, is that a guidance on timing of the data? And just on that, can you remind us kind of the design of that trial and what to be expected?

    嗨,謝謝讓我提問。恭喜進展順利。我只是想請教,關於口腔過敏測試以及目前即將出來的數據,你們談到「完成」。但所謂完成,是否也代表數據發布時點的指引?另外,也能否提醒我們該試驗的大致設計,以及預期會看到什麼?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yeah. I'll let Dr. Kraus walk you through that.

    好的。我請 Kraus 醫師帶你了解。

  • Carl Kraus - Chief Medical Officer

    Carl Kraus - Chief Medical Officer

  • Yeah. Thanks for the question. The design of the study is meant to characterize whether or not changes in the physiology of the oral cavity have an influence on the pharmacokinetics of Anaphylm. So the way that the study is designed is, we take individuals who have a history of Oral Allergy Syndrome. We challenge them to make sure that they actually have those kinds of symptoms and signs that they historically state that they have.

    好的。謝謝你的問題。這項研究的設計旨在描述:口腔生理狀態的變化是否會影響 Anaphylm 的藥物動力學。因此,研究的設計方式是:我們納入有口腔過敏症候群病史的受試者。我們會對他們進行誘發測試,以確認他們確實具有其過往所述的那類症狀與徵象。

  • Once confirmed, then they will be challenged with the fruit that causes the symptoms. They will be provided and dosed with Anaphylm. The pharmacokinetics will be evaluated and that will be compared to the same situation but without the challenge as well as with the intramuscular administration of Adrenalin.

    一旦確認後,接著會用引發症狀的水果對他們進行誘發。然後會提供並給予 Anaphylm 劑量。我們將評估其藥物動力學,並與相同情境但不進行誘發的情況,以及腎上腺素肌肉注射給藥的情況進行比較。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • And on timing, Frank, yes, our guidance on timing is that we expect top-line data from that study either at the end of this quarter or early in Q4.

    至於時程,Frank,是的,我們對時程的指引是:預期該研究的主要(top-line)數據會在本季末或第四季初公布。

  • François Brisebois - Analyst

    François Brisebois - Analyst

  • Okay. Great. And then maybe on Anaphylm, we talked about Libervant and the sales force. And you talked about a lot of pre-commercial efforts on Anaphylm but can you help us segment, maybe you talked about the high prescribers. But is this kind of a KOL mindset where it's very concentrated or is this really a broad population? How -- like what percentage is the high prescribers? I'm just trying to get a feel for how doable this is for a company your size and what goes into the discussion or strategy of looking to a bigger partner. I just trying to decide a little bit about these prescribers and what kind of salesforce it would require. Thank you.

    好的。很好。接著可能關於 Anaphylm,我們談到 Libervant 與銷售團隊。你也提到 Anaphylm 有很多上市前的工作,但你能否幫我們做個區分?你提到高處方者。但這是否像 KOL(關鍵意見領袖)那樣高度集中,還是其實是很廣泛的人群?像是——高處方者大概占多少比例?我只是想了解,以你們公司這樣的規模,這件事的可行性如何,以及在尋找更大型合作夥伴的討論或策略上會考量哪些因素。我想更清楚這些開立處方者的樣貌,以及需要什麼樣規模的銷售團隊。謝謝。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Sure, I'll let Sherry take that.

    當然,我請 Sherry 回答。

  • Sherry Korczynski - Senior Vice President of Sales and Marketing

    Sherry Korczynski - Senior Vice President of Sales and Marketing

  • Thanks for the question. I greatly appreciate it. Based on the significant experience I have in this market, this is a well-worn path. We know how many reps it would take to reach those high prescribers and we'll start our ACP targeting and sizing, rightsizing salesforce work in early 2025. I think that when you think about this market, it is spread over multiple specialties.

    謝謝你的問題。我非常感謝。基於我在這個市場的豐富經驗,這是一條相當成熟、走過很多次的路徑。我們知道需要多少位業務代表才能觸及那些高處方者;我們也會在 2025 年初開始進行 ACP 的目標設定與規模評估,以及銷售團隊的適度配置(rightsizing)工作。我認為當你思考這個市場時,它分布在多個專科領域。

  • However, the high prescribers are concentrated in allergists and pediatricians. And so we feel very good about the opportunity we have to really penetrate those high-prescribing allergists and pediatricians and that will be our key focus upon launch.

    然而,高處方者主要集中在過敏專科醫師與小兒科醫師。因此,我們對於能夠深入滲透那些高處方量的過敏科與小兒科醫師的機會感到非常有信心,而這也將是我們上市後的關鍵重點。

  • François Brisebois - Analyst

    François Brisebois - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Ram Selvaraju, H.C. Wainwright.

    Ram Selvaraju,H.C. Wainwright。

  • Ram Selvaraju - Analyst

    Ram Selvaraju - Analyst

  • Hi, Thanks very much for taking my questions. Firstly, with respect to Anaphylm, I was wondering if you could provide us with some more detail on what you plan to discuss at the upcoming showcase event. And in particular, if you're going to discuss ways in which you're going to differentiate Anaphylm from neffy assuming those products are both on the market simultaneously, particularly with respect to the overall marketing message that you expect to utilize.

    嗨,非常感謝讓我提問。首先,關於 Anaphylm,我想請問你們能否更詳細說明在即將到來的展示活動(showcase event)上計畫討論哪些內容。特別是,若假設 Anaphylm 與 neffy 兩個產品同時在市場上,你們是否會討論如何讓 Anaphylm 與 neffy 做出差異化,尤其是在你們預期採用的整體行銷訊息方面。

  • And also, if you could comment at all, assuming you're comfortable doing so, to what extent do you believe you might be able to utilize a more efficient, smaller commercial footprint to support the commercialization of Anaphylm versus what conceivably would be necessary for neffy? Thanks.

    另外,如果你們方便評論的話,假設你們願意談,與 neffy 相比,你們認為在推動 Anaphylm 商業化時,能在多大程度上採用更有效率、規模更小的商業佈局(commercial footprint)?而 neffy 可能需要的規模又會是什麼樣子?謝謝。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Thanks, Ram. So I will -- we, as the team here, we'll try to make sure we address all of your -- all parts of your question, but if I missed one, please let me know. First, on our upcoming Investor Day, as -- and this may be underappreciated based on how much we've talked about it.

    謝謝你,Ram。所以我會——我們這個團隊會盡量確保回答你問題的所有——所有部分;但如果我漏掉了哪一點,請告訴我。首先,關於我們即將舉行的投資人日(Investor Day),如同——而且基於我們談論它的頻率,這點可能被低估了。

  • But when we talk about our Adrenaverse epinephrine prodrug platform, Anaphylm actually came out of that work. So we will discuss Anaphylm at the Investor event, but I'm going to pass it over to Dr. Wargacki for a second here, and he can tell you a little bit more about what we're really excited to talk about at that Investor event outside of Anaphylm.

    但當我們談到 Adrenaverse 腎上腺素前藥平台時,Anaphylm 其實就是從那項工作中誕生的。因此我們會在投資人活動上討論 Anaphylm,但我先把話題交給 Wargacki 醫師一下,他可以跟你多談一些,除了 Anaphylm 之外,我們在那場投資人活動上真正很期待分享的內容。

  • Stephen Wargacki - Chief Science Officer

    Stephen Wargacki - Chief Science Officer

  • Thanks, Ram. Yeah. So with the Adrenaverse platform, we learned a lot of stuff in the genesis of Anaphylm, and what we've done is we've progressed that through now to expand that technology. And we're really excited to come talk to everybody here shortly. The progression we've done on the nonclinical front and secure our intellectual property as we prepare for our interaction with the agency at the end of the year.

    謝謝你,Ram。是的。在 Adrenaverse 平台方面,我們在 Anaphylm 的起源階段學到了很多東西,而我們所做的是把這些進一步推進,並擴展這項技術。我們非常期待很快能與大家分享。我們在非臨床方面所取得的進展,以及在準備於年底與主管機關互動之際,如何鞏固我們的智慧財產權。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yes. So the point I'll put in is, make sure you attend. We think it will be worth everyone's time. In terms of the differentiation of Anaphylm versus neffy, I'm going to pass it over to Sherry in a second here. But on that, in particular, just at a macro level, we think -- we believe we are very differentiated from neffy. So we don't see ourselves in any way as being a product that will have an issue separating ourselves, and I'll let Sherry walk you through some of the highlights from her perspective.

    是的。所以我要強調的是:務必參加。我們認為這會值得大家花時間。至於 Anaphylm 相對於 neffy 的差異化,我接下來會把話題交給 Sherry。不過就這點而言,特別是在宏觀層面上,我們認為——我們相信我們與 neffy 有非常明顯的差異化。因此我們不認為自己在任何方面會遇到難以區隔的問題;我讓 Sherry 從她的角度帶大家看一些重點。

  • Sherry Korczynski - Senior Vice President of Sales and Marketing

    Sherry Korczynski - Senior Vice President of Sales and Marketing

  • Again, thank you for that question. We've spent a great deal of time conducting market research to understand what our key competitive advantages are in the minds of physicians and patients. And as I mentioned earlier, the unmet needs in this market are well known, well-articulated. Anaphylm offers such a unique competitive advantage in terms of addressing those needs. \The beauty of Anaphylm is the simplicity of Anaphylm. We know that based on our data, it works as quickly and as safely as the gold standard EpiPen.

    再次謝謝你的問題。我們投入了大量時間進行市場調查,以了解在醫師與病患心目中,我們的關鍵競爭優勢是什麼。而如我先前提到的,這個市場的未被滿足需求是眾所周知且表述清楚的。Anaphylm 在滿足這些需求方面提供了非常獨特的競爭優勢。\Anaphylm 的美妙之處在於它的簡單性。我們知道,根據我們的數據,它的起效速度與安全性可與黃金標準 EpiPen 一樣。

  • Next, you don't have a needle and there is no device. Third, it's orally delivered, that is unmatched, and it has been a desire for -- at least the last two decades based on my experience, is that to have an orally delivered product is a game changer in treating the patient with severe allergies and anaphylaxis.

    接下來,你不需要針頭,也沒有任何裝置。第三,它是口服給藥,這是無可匹敵的;而且依我經驗,至少在過去二十年裡,能有一個口服給藥的產品一直是大家的期待,因為這會徹底改變對重度過敏與過敏性休克患者的治療方式。

  • We know from our research, and Dan had mentioned earlier in his comments about our ability to better withstand heat -- withstand exposure, excuse me, full heat, washing machines, et cetera. But perhaps most importantly, and if you take nothing else away from this, it is the one and only epinephrine product that can fit into any lifestyle, and it doesn't require an active carry decision.

    我們從研究中得知,Dan 先前在評論中也提到,我們的產品更能耐熱——更能承受暴露,抱歉,是承受完全高溫、洗衣機等情境。但也許最重要的是——如果你只記住一件事——它是唯一一個能融入任何生活型態的腎上腺素產品,而且不需要做出「主動攜帶」的決定。

  • So it fits and can always be kept in a wallet, a small change purse, in the credit card holder that you put on the back of your phone. So I believe, based on my experiences in this therapeutic area, we will have the best form of epinephrine upon approval by FDA for patients and caregivers alike.

    因此它很合適,並且可以一直放在錢包、小零錢包,或是你放在手機背面的信用卡夾裡。所以我相信,基於我在這個治療領域的經驗,一旦獲得 FDA 核准,我們將為患者與照護者提供最好的腎上腺素劑型。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Thanks, Sherry. And Ram, let me -- I think the last part of your question was around, really around sales coverage and distribution, right? How are we thinking about that? And I think you mentioned a more efficient, smaller footprint. As I put in my prepared comments, I think you hit the nail in the head, so to speak. When I look at where we are right now with $90 million in our -- in the bank as of June 30, and the progression of our programs versus where we were two years ago, I am ecstatic with what we have done.

    謝謝你,Sherry。Ram,讓我——我想你問題的最後一部分其實是關於銷售覆蓋與通路分銷,對吧?我們怎麼思考這件事?而且我想你提到更有效率、更小的覆蓋規模。如同我在事先準備的評論中所說,我覺得你說到重點了。當我看到截至 6 月 30 日我們帳上有 9,000 萬美元現金,以及我們各項計畫的進展相較於兩年前的狀況,我對我們所完成的成果感到非常振奮。

  • Now the task is making sure that we are able to bring the product to all patients and that we are able to do that efficiently. We clearly, at this time, don't plan on being a PCP call point-based salesforce. So the efforts that we are focused on, as Sherry walked you through or very targeted and they're very specific to the high prescribers.

    現在的任務是確保我們能把產品帶給所有患者,並且能以有效率的方式做到。很明確地,目前我們不打算建立以基層照護醫師(PCP)拜訪點為主的銷售團隊。因此,我們聚焦的工作——如 Sherry 帶你們走過的——非常精準,且是針對高處方量醫師的非常具體策略。

  • As I mentioned in my prepared comments, we do have some inbound interest that we're walking through. And as we get closer to our launch, we will look at how do we cover the entire market to make sure we maximize patients' ability to get the product.

    如我在事先準備的評論中提到,我們確實收到一些主動洽詢的合作意向,正在逐一評估。隨著我們更接近上市,我們會再檢視如何覆蓋整個市場,以確保最大化患者取得產品的能力。

  • Ram Selvaraju - Analyst

    Ram Selvaraju - Analyst

  • Great. And then just two very quick additional ones. I was wondering if Ernie could comment on the components driving the updates to 2024 top-line guidance. And in particular, I wanted clarity on two aspects of this. One is the extent to which the revenue reported in the second quarter was effectively non-cash impacting because of what you disclosed in the press release were effectively agreement terminations and recognition of deferred revenue.

    很好。接著還有兩個非常快的補充問題。我想請 Ernie 說明一下,推動 2024 年營收(top-line)指引更新的構成因素。特別是我想釐清其中兩點。第一是,第二季所報告的營收在多大程度上實際上對現金沒有影響,因為你們在新聞稿中揭露那主要是協議終止以及遞延收入的認列。

  • And also, when we look at the updated guidance number, how much of that is being driven by improved expectations for organic growth of underlying revenue streams, like for example, the royalties that you expect to receive from partners on partnered products?

    另外,當我們看更新後的指引數字時,其中有多少是由於對基礎營收來源的有機成長預期改善所驅動,例如你們預期從合作夥伴的合作產品中收到的權利金?

  • Ernie Toth - Chief Financial Officer, Senior Vice President

    Ernie Toth - Chief Financial Officer, Senior Vice President

  • Hi, Ram, thank you, good to talk to you. So the guidance for 2024, the revenue is increased because of the deferred revenue recognition due to the termination of the two agreements as we mentioned, back in May. We went through a strategic review to focus on -- so we're able to focus our time, not only on profitable products but also from a long-term perspective, but also from a time allocation resources of being able to focus both on Anaphylm and on the expanded launch now of Libervant.

    嗨,Ram,謝謝你,很高興和你交流。關於 2024 年指引,營收上調是因為我們如先前提到的,在 5 月終止兩項協議後,認列了遞延收入。我們進行了一次策略性檢視,以便能聚焦——讓我們能把時間投入在不僅是具獲利性的產品上,也從長期角度出發,同時在時間與資源配置上,能同時聚焦於 Anaphylm,以及目前擴大推進的 Libervant 上市。

  • So the revenue guidance for the year does include those terminations. As you mentioned, they are non-cash items. We actually received that cash back in the '21, '22 time frame. So that's cash that we had and now it's just a non-cash recognition of that revenue.

    因此,年度營收指引包含了這些終止協議的影響。如你所提到,這些是非現金項目。我們其實在 2021、2022 年那段期間就已收到現金。所以那是我們當時已持有的現金,現在只是把那部分營收以非現金方式認列出來。

  • When we look at our, again, the guidance for the year, we've taken those into account when we look at our demand for Suboxone for the remainder of the year. We see that increasing from the levels that we've seen in the first half of the year. And then from an EBITDA perspective, we have built in now which was not in our prior guidance was the Libervant launch cost that we had and some additional spending -- the timing of spending on the pre-commercial spend for Anaphylm.

    再看我們——同樣是年度指引——我們在評估今年剩餘期間 Suboxone 的需求時,已把這些因素納入考量。我們看到其需求將高於上半年所見的水準。另外從 EBITDA 的角度,我們現在也納入了先前指引未包含的 Libervant 上市成本,以及一些額外支出——也就是 Anaphylm 商業化前支出的投入時點。

  • So all total, the revised guidance includes the recognition of deferred revenue, timing of Suboxone for the remainder of the year on an EBITDA basis, timing of the Libervant launch cost and also some commercial spend, pre-commercial spend for Anaphylm.

    總體而言,修訂後的指引包含:遞延收入的認列、今年剩餘期間 Suboxone 的時點(在 EBITDA 基礎上)、Libervant 上市成本的時點,以及 Anaphylm 的部分商業支出與商業化前支出。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • So Ram, the only thing I'd add to what Ernie said is, if you back away from the ins and outs that Ernie walked you through, we're right where we wanted to be. The investment dollars we have are going to commercial and to the Anaphylm development and we are on track with all of the expectations that we have set over the last two quarters.

    Ram,我唯一要補充 Ernie 所說的是:如果你先不看 Ernie 剛剛帶你走過的各項細節,我們目前正處於我們想要的位置。我們的投資資金正投入在商業化以及 Anaphylm 的開發上,而且我們在過去兩季所設定的所有預期上都按計畫推進。

  • Ram Selvaraju - Analyst

    Ram Selvaraju - Analyst

  • Great. Thank you very much.

    很好。非常感謝。

  • Operator

    Operator

  • Thomas Flaten, Lake Street Securities.

    Thomas Flaten,Lake Street Securities。

  • Thomas Flaten - Analyst

    Thomas Flaten - Analyst

  • Dan, in the press release, you mentioned that you'll be submitting for the 6 to 12 year old age bracket for Libervant. What data do you have or do you need to get to enable that submission to go into FDA?

    Dan,在新聞稿中你提到,你們將針對 Libervant 提交 6 到 12 歲年齡層的申請。你們目前有哪些數據,或還需要取得哪些數據,才能讓該申請送進 FDA?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yeah. We did that work years ago as Thomas, you probably remember. So that is strictly a paper exercise at this point.

    是的。我們多年前就完成那項工作了,Thomas,你可能還記得。所以目前嚴格來說只是文書作業。

  • Thomas Flaten - Analyst

    Thomas Flaten - Analyst

  • Okay. Got it. And then for the Investor Day coming up and maybe some of the unveiling around the Adrenaverse opportunity. I'm trying to interpret the press release. Can I read into that, that you'll be unveiling additional products beyond AQST-108 or is it more of a 108 focused presentation?

    好的。了解。接著關於即將到來的投資人日,以及可能會揭露一些關於 Adrenaverse 機會的內容。我在解讀新聞稿。我是否可以理解為,你們會揭露 AQST-108 以外的其他產品,還是會更偏向以 108 為主的簡報?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yeah. Our plan is to -- we know we have continued to talk about Adrenaverse and 108 without giving a lot of detail to you, and we appreciate everyone's patience. As Steve mentioned before, intellectual property being in position is very important before you have those days.

    是的。我們的計畫是——我們知道我們一直在談 Adrenaverse 和 108,但沒有提供太多細節給各位,我們也感謝大家的耐心。如 Steve 先前提到,在舉辦那樣的活動之前,智慧財產權布局到位非常重要。

  • So our one of the things we'll do, as Steve mentioned, is walk you through the science because I don't think we've given you a fair view on why we're so excited about it. We will walk through the specific indication for 108, which we haven't given you yet. But in that discussion, we believe you will walk away seeing that while we're announcing 108 in an indication, there are multiple programs that could come after 108.

    因此我們會做的一件事——如 Steve 提到的——是帶大家走過科學面,因為我認為我們還沒有讓各位充分理解我們為何如此興奮。我們也會說明 108 的具體適應症,這部分我們之前尚未對外揭露。但在那段討論中,我們相信各位會理解:即使我們是在某個適應症上宣布 108,108 之後仍可能有多個計畫接續推出。

  • Thomas Flaten - Analyst

    Thomas Flaten - Analyst

  • Great. And then just one question, just a follow-up on something you said, Dan, in response to another question, that you had some inbound interest in Anaphylm. Is that from a commercial partnering perspective or maybe something broader like an acquisition of the entire product?

    很好。最後一個問題,針對你剛才在回覆另一個問題時提到的:你們收到一些對 Anaphylm 的主動洽詢意向。那是從商業合作夥伴的角度,還是更廣泛的,例如收購整個產品?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yes. It's been across the board. So as we get closer, other companies in our space have more of an eye towards where we are and what's happening. We've had inquiries that span the spectrum.

    是的。這是全面性的。因此,隨著我們越來越接近,與我們同一領域的其他公司會更關注我們目前的位置以及正在發生的事情。我們收到的詢問涵蓋了各種面向。

  • Thomas Flaten - Analyst

    Thomas Flaten - Analyst

  • Got it. I appreciate taking the question. Thank you.

    了解。感謝讓我提問。謝謝。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Thank you, Thomas.

    謝謝你,Thomas。

  • Operator

    Operator

  • Jason Butler, Citizens JMP.

    Jason Butler,Citizens JMP。

  • Jason Butler - Analyst

    Jason Butler - Analyst

  • Hi. Thanks for taking the question. I just want to come back to the Anaphylm pediatric study. What -- given that you've already had dialogue with FDA about the design of the study, what's the gating factor to starting the study? And I guess, that's a different way, what is it that you need to get from the pre-NDA meeting to -- before you start that study?

    嗨。謝謝讓我提問。我想再回到 Anaphylm 的兒科研究。鑑於你們已經就研究設計與 FDA 進行過對話,啟動該研究的關鍵門檻因素是什麼?換個方式問,在你們開始那項研究之前,你們需要從 pre-NDA 會議中獲得什麼?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • I'll let Carl take that one.

    我讓 Carl 來回答這題。

  • Carl Kraus - Chief Medical Officer

    Carl Kraus - Chief Medical Officer

  • Yes, Jason, thanks for the question. Really, it's making sure that we have alignment with the agency that the adult data set meet muster and we agree on using those data to act as the tollgate for starting a pediatric program. So that's really the one of the key critical questions we're going to secure out of the pre-NDA meeting.

    是的,Jason,謝謝你的問題。主要是要確保我們與主管機關在觀點上達成一致:成人資料集符合要求,並且我們同意使用這些資料作為啟動兒科計畫的關卡(tollgate)。因此,這確實是我們將在 pre-NDA 會議中要確認的關鍵核心問題之一。

  • Jason Butler - Analyst

    Jason Butler - Analyst

  • Okay. Thank you.

    好的。謝謝。

  • Operator

    Operator

  • Gary Nachman, Raymond James.

    Gary Nachman,Raymond James。

  • Gary Nachman - Analyst

    Gary Nachman - Analyst

  • Hey, good morning, guys. So I know you still have to meet with FDA on Anaphylm in the fourth quarter. But are you anticipating an AdCom for Anafilm like neffy had? Or do you think with all your conversations with FDA, supportive studies, that wouldn't be necessary? And since neffy could get approved on October 2, just what do you think the read-through is there for you guys from a regulatory step?

    各位早安。我知道你們仍需要在第四季就 Anaphylm 與 FDA 會面。但你們是否預期 Anafilm 會像 neffy 一樣召開 AdCom(諮詢委員會會議)?或者你們認為,基於你們與 FDA 的多次溝通以及支持性研究,可能不需要?另外,既然 neffy 可能在 10 月 2 日獲准,你們認為從監管步驟的角度,這對你們的「讀穿」(read-through)意義是什麼?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yeah. I'll take the -- your second question first, and then I'll hand it over to Carl to talk about his views on the AdCom. It's always tricky to look at someone else's application and have a read-through to your program. So our engagement with the FDA has been very open, transparent from our perspective, consistent, and supportive of what we are looking to accomplish.

    是的。我先回答你的第二個問題,然後再交給 Carl 談談他對 AdCom 的看法。從別人的申請案推導到自己的計畫,向來都很棘手。就我們而言,我們與 FDA 的互動一直非常開放、透明(以我們的角度來看)、一致,且對我們想要達成的目標是支持的。

  • I don't -- I haven't been in the discussions that the other -- that our competitor has had. So I think we're all looking to see on October 2, how their product fares and whether if they don't get approval, whether that's related to something that is specific to their product or something that is in the way they've interacted with the FDA. We just, we don't have any insight into that.

    我沒有參與其他公司——也就是我們競爭對手——與 FDA 的討論。所以我想大家都在看 10 月 2 日他們的產品結果如何;如果他們未獲核准,原因究竟是其產品本身的特定問題,還是他們與 FDA 互動方式的問題。我們對此沒有任何洞見。

  • In terms of the AdCom, I'll let Carl give you his thoughts.

    至於 AdCom,我讓 Carl 來分享他的想法。

  • Carl Kraus - Chief Medical Officer

    Carl Kraus - Chief Medical Officer

  • Yeah, I know. Thanks Jon. Look, we believe that the program continues down a path of declining risk, and whether or not the division of one to secure a counsel from the Advisory Committee, that is the decision that they have to make. I can't try and get inside the FDA's head. But I do believe that no matter what, we continue to go down this path of defining risk and that's hopefully in the position of decreasing risk for an AdCom as well. But of course, I can't speak for the FDA.

    是的,我知道。謝謝你,Jon。我們認為這個計畫正沿著風險逐步下降的路徑前進;至於該部門是否要尋求諮詢委員會的建議,那是他們必須做的決定。我無法揣測 FDA 的想法。但我確實相信,不論如何,我們都會持續走在界定風險的道路上,而這也希望能讓召開 AdCom 的風險同樣降低。當然,我無法代表 FDA 發言。

  • Gary Nachman - Analyst

    Gary Nachman - Analyst

  • Okay. And then just with Libervant, as you're building out that infrastructure a little bit, just talk about how you'll be able to leverage that effort potentially for Anaphylm, where there's going to be some overlap. And with respect to the inbound interest on Anaphylm, I would imagine that it's more likely to be for the primary care, someone who has a primary care capability, but maybe you could just elaborate on that a little bit, Dan?

    好的。另外,關於 Libervant,當你們稍微建立起那套基礎設施時,請談談你們將如何把這些努力可能延伸運用到 Anaphylm 上,因為兩者會有一些重疊。再者,關於外部主動接洽對 Anaphylm 的興趣,我想更可能是來自具備基層醫療(primary care)能力的夥伴,但 Dan 你能否再多說一點?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yes. For whatever reason, Gary, I'll start with your second question again here. So of course, primary care would be an interesting addition to our capabilities for Anaphylm. It's early days in terms of any discussions that we're having. So my view would be, it will be quarters of time before we have a view on what we will or won't do with someone else on Anaphylm. In terms of Libervant, of course, they're -- Libervant, excuse me, there are some really nice infrastructure pieces that do tie to Anaphylm. I'll let Sherry give you her thoughts on some of those infrastructure overlaps.

    是的。不知為何,Gary,我這裡也先從你的第二個問題開始。當然,對 Anaphylm 而言,基層醫療會是我們能力的一個有趣補強。目前就我們正在進行的任何討論而言,都還在非常早期的階段。所以我的看法是,可能還需要以「季」為單位的一段時間,我們才會對於是否與他方在 Anaphylm 上合作有明確看法。至於 Libervant,當然——Libervant,抱歉——有一些很不錯的基礎設施要素確實能與 Anaphylm 連結。我讓 Sherry 來談談其中一些基礎設施重疊之處。

  • Sherry Korczynski - Senior Vice President of Sales and Marketing

    Sherry Korczynski - Senior Vice President of Sales and Marketing

  • Yes. Obviously, it's important, it will start to lay a foundation for all of our commercial activities between salesforce, marketing will give us synergies and commercial operations. So we feel strongly that this is a really nice start for us as we prepare for the launch of Anaphylm as well.

    是的。顯然這很重要,因為它將在我們所有商業活動上奠定基礎;從銷售團隊到行銷,都會帶來協同效益以及商業營運面的綜效。因此,我們非常有信心,這會是我們在為 Anaphylm 上市做準備時一個非常好的起點。

  • Gary Nachman - Analyst

    Gary Nachman - Analyst

  • Okay. Great. Thank you very much.

    好的。很好。非常感謝。

  • Operator

    Operator

  • James Molloy, Alliance Global Partners.

    James Molloy,Alliance Global Partners。

  • James Malloy - Analyst

    James Malloy - Analyst

  • Hey, guys. Thank you very much for taking my questions. Just a quick question for Ernie, just to clarify as well. So the updated guidance top line does include the $10 million one-timer. So excluding that for top line and EBITDA, should we just stay with the prior guidance on both those items as a more sort of cash-driven EBITDA and top line?

    各位好。非常感謝讓我提問。我有個給 Ernie 的快速問題,也想再釐清一下。更新後的指引在營收(top line)上確實包含那筆 1,000 萬美元的一次性項目。因此,若在營收與 EBITDA 上排除該項一次性因素,我們是否應該在這兩項上維持先前的指引,作為更偏現金驅動的 EBITDA 與營收水準?

  • Ernie Toth - Chief Financial Officer, Senior Vice President

    Ernie Toth - Chief Financial Officer, Senior Vice President

  • Hi, Jim. So again, the amount of the deferred revenue that was recognized was noncash. We got that cash two years ago. So that is included in the revised guidance for 2024 that does contribute to EBITDA. But if your question is about annualizing our results or I don't know if that's exactly what you're asking, there will be some increased expenses as we get into the second half of the year around the Libervant launch activities, some increased commercials -- pre-commercial spend for Anaphylm in addition to some other timing issues around revenue and expenses.

    嗨,Jim。所以再說一次,被認列的遞延收入金額是非現金項目。那筆現金我們在兩年前就已經收到了。因此,它已包含在我們 2024 年修訂後的指引中,並且會對 EBITDA 有所貢獻。但如果你的問題是關於將我們的結果年化,或我不確定你是否是這個意思;隨著我們進入下半年,圍繞 Libervant 上市活動會有一些費用增加,另外還會有 Anaphylm 的一些商業化前支出增加,以及其他一些收入與費用在時點上的因素。

  • So I think backing out the onetime revenue for -- that is included in both revenue and contributes to EBITDA, you could get to another number. That's not something we give.

    所以我認為,把那筆一次性收入——它同時包含在營收中並對 EBITDA 有貢獻——扣除後,你可以得到另一個數字。但那不是我們會提供的。

  • James Malloy - Analyst

    James Malloy - Analyst

  • Thank you. Understood. It actually ties in with the next question, too. The R&D and G&A in the current quarter, is that the number that we should expect going forward? Or we just pay any material changes up or down on those?

    謝謝。了解。這其實也和下一個問題有關。本季的研發(R&D)與一般及行政(G&A)費用,是否就是我們往後應該預期的水準?或者在這些項目上,是否會有任何重大的上或下變動需要注意?

  • Ernie Toth - Chief Financial Officer, Senior Vice President

    Ernie Toth - Chief Financial Officer, Senior Vice President

  • Well, again, some of these expenses, we would expect to increase a little bit in the second part of the year, R&D, and annualizing it. Remember that we do have some of these studies that are coming to a conclusion in the second part of the year.

    嗯,再次說明,其中一些費用我們預期在下半年會小幅增加,包括研發費用,以及將其年化後的影響。請記得,我們確實有一些研究會在下半年接近結論。

  • In addition, there is some of the selling expenses that is included in SG&A around the Libervant expanded launch and the pre-commercial spend for Anaphylm would be embedded in those numbers. And all of that is included in my guidance for the -- our guidance for the year.

    此外,SG&A 中也包含了一些銷售費用,與 Libervant 擴大上市相關,以及 Anaphylm 商業化前的支出也會反映在這些數字中。而這些都已納入我對——我們對全年所提供的指引之中。

  • James Malloy - Analyst

    James Malloy - Analyst

  • All right. Thank you. And maybe a question for Dan, the topical gel, could you walk us through the Phase 2 trial design? And one of the things you guys talked about, the Adrenaverse, the $1 billion opportunity, could you walk through what sort of the some of the big pillars of that $1 billion opportunity could be?

    好的。謝謝。另外也許有個問題想問 Dan,關於外用凝膠,你能帶我們了解第二期試驗的設計嗎?還有你們提到的 Adrenaverse、10 億美元的機會,你能說明一下這個 10 億美元機會的幾個主要支柱可能是什麼嗎?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Jim, I want to make sure you attend our Investor Day, so I'm going to give you the teaser that, that is exactly some of the things you'll hear at our Investor Day in the coming months. So we look forward to walking through one away the indication that we're seeing and some of our thoughts on what the Phase 2 way will look like.

    Jim,我想確保你會參加我們的投資人日,所以我先給你一點預告:接下來幾個月的投資人日,你將會聽到的內容正是你問的這些。因此,我們很期待屆時帶大家逐一說明我們看到的適應症方向,以及我們對第二期路徑可能會如何呈現的一些想法。

  • James Malloy - Analyst

    James Malloy - Analyst

  • I'll be there with those on. Could you walk through the 108 topical gel Phase 2 trial design? Please.

    我會到場。你能說明一下 108 外用凝膠第二期試驗的設計嗎?拜託。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • That's -- Jim, maybe I wasn't clear, so my apologies. We're not providing that ahead of the Investor Day. That is one of the things we want to share with everyone in the context of our science program and where we're going and walking through that today would be ahead of all the things we need to share with you.

    那個——Jim,也許我剛才沒有講清楚,先跟你致歉。我們不會在投資人日之前提供這些資訊。這是我們希望在投資人日、結合我們的科學計畫與未來方向,與大家分享的內容之一;今天就先談會早於我們需要對你們完整揭露的其他事項。

  • James Malloy - Analyst

    James Malloy - Analyst

  • Understood. My apologies for missing that answer. And then well also, on the R&D Day, when you talk about the number of reps for the Anaphylm self-launch, if you should indeed self-launch. Could you walk through -- again, maybe this will be in the R&D Day as well, the go, no-go on a partner versus self-launch.

    了解。抱歉我剛才漏聽了那個回答。另外,在研發日(R&D Day)上,當你談到 Anaphylm 自行上市(如果你們確實選擇自行上市)的業務代表人數時,你能否說明——同樣也許這也會在研發日提到——在合作夥伴與自行上市之間,做出 go/no-go 決策的考量?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yes. The -- we will, of course, look, Anaphylm is the center theme of our company at this time, right? So we of course, at the Investor Day, we'll start with any updates we have on Anaphylm, anything that we think is meaningful to share and how it ties to our Adrenaverse technology. In terms of the salesforce, I think Sherry gave you her thoughts before and her timing on how we go from where we are today to a very specific plan. Just one of the things I think is important that Sherry said is that this is a well-worn path. She's done it before, she understands it. So I don't think there'll be any surprises there.

    是的。——我們當然會評估;Anaphylm 目前是我們公司的核心主題,對吧?因此在投資人日,我們會先從 Anaphylm 的任何最新進展開始,分享我們認為值得揭露的重點,以及它如何與我們的 Adrenaverse 技術相連結。至於銷售團隊,我想 Sherry 先前已分享她的看法,以及我們如何從目前狀態推進到一個非常具體計畫的時間點。我認為 Sherry 提到的一點很重要:這是一條走過很多次的成熟路徑。她以前做過,也理解這個流程。所以我不認為那方面會有任何意外。

  • In terms of any distribution agreements or alignment with other companies, just to make sure I've clarified that. Where we are today is we've had inbound inquiries. We are just beginning to think about what type of arrangement we may or may not want to have. I would say it is not imminent nor do we want it to be imminent that something like that were to be put in place. As we go through the next two quarters, those conversations will develop as we'll share this plan, and then we'll know exactly as a company where we want to place our bets, so to speak.

    至於任何經銷協議或與其他公司的合作安排,我再確認一下我是否已說清楚。我們目前的狀況是:我們收到了一些主動洽詢(inbound inquiries)。我們才剛開始思考我們可能想要、或不想要採取什麼樣的安排。我會說,這並不迫在眉睫,我們也不希望它變得迫在眉睫——也就是說,並不急著要把這類安排落地。在接下來兩個季度,隨著我們分享這個計畫,這些對話會逐步發展;屆時我們也會非常清楚,作為一家公司我們要把賭注押在哪裡——可以這麼說。

  • Operator

    Operator

  • Thank you. I'm showing no further questions at this time. I will now turn the call back over to Dan farmer for any closing.

    謝謝。我這邊顯示目前沒有其他問題。我現在把電話會議交回給 Dan Farmer,請他做結語。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Thank you, Olivia. Well, of course, as always, we appreciate your time this morning. As you heard, we are truly excited about the progress the company has made over the last year. We're confident in our Anaphylm development program. We're ready to expand our sales efforts for Libervant in the 2 to 5 year old space. And we have meaningful in-house technology to refill our pipeline. This is a great place to be. We hope you have a great rest of your day, and we look forward to our future interactions.

    謝謝你,Olivia。當然,一如往常,我們感謝各位今天早上撥冗參與。如各位所聽到的,我們對公司在過去一年所取得的進展感到非常振奮。我們對 Anaphylm 的開發計畫充滿信心。我們已準備好擴大 Libervant 在 2 至 5 歲族群市場的銷售推廣。而且我們擁有具實質意義的內部技術,可用來補充我們的產品管線。這是一個很好的位置。祝各位今天剩下的時間一切順利,也期待未來與各位的互動。

  • Operator

    Operator

  • Ladies and gentlemen, at this conference for today. Thank you for your participation. You may now disconnect.

    各位女士、先生,今天的電話會議到此結束。感謝各位的參與。您現在可以掛線。